Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

Table 3 Parent-reported outcomes at cross-sectional visit in patients still receiving ETN

	No assessed
Median (IQR) physical function score^a	420	0 (0; 3)
No (%) of patients with physical function score = 0	420	220 (52.4)
Median (IQR) HRQL score^b	417	2 (0; 5)
No (%) of patients with HRQL score > 1 DS above the mean of healthy children	417	92 (22.1)
Median (IQR) HRQL PhH score^c	417	1 (0; 3)
No (%) of patients with HRQL PhH score > 1 DS above the mean of healthy children	417	203 (48.7)
Median (IQR) HRQL PsH score^c	417	1 (0; 3)
No (%) of patients with HRQL PsH > 1 DS above the mean of healthy children	417	82 (19.7)
Median (IQR) VAS well-being^d	420	0.5 (0; 3)
No (%) of patients with VAS well-being = 0	420	193 (46)
Median (IQR) VAS pain^d	420	0 (0; 2,5)
No (%) of patients with VAS pain = 0	420	215 (51.2)
No (%) of patients with VAS pain ≤1	420	289 (68.8)
No (%) of patients with VAS pain from 1.5 to 5	420	99 (23.6)
No (%) of patients with VAS pain >5	420	32 (7.6)
Median (IQR) VAS disease activity^d	420	0 (0; 2)
No (%) of patients with VAS disease activity = 0	420	224 (53.3)
No (%) of patients with no morning stiffness	420	319 (76)
Disease activity state
No (%) of patients with remission	421	286 (67.9)
No (%) of patients with continued activity	421	86 (20.4)
No (%) of patients with disease flare	421	49 (11.6)
No (%) of parents satisfied with their child’s illness outcome	399	330 (82.7)

IQR interquartile range, HRQL health-related quality of life, PhH Physical Health, PsH Psychosocial Health, VAS visual analog scale
^aScore ranges from 0 (no disability) to 30 (maximum disability)
^bScore ranges from 0 to 30, higher scores indicate worse HRQL
^cScore ranges 0–15, higher scores indicate worse HRQL
^dAll VAS range from 0 (best) to 10 (worst)

ISSN: 1546-0096